Quality of life is associated with chronic inflammation in schizophrenia: A cross-sectional study

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Faugere, M ^a,b   Micoulaud Franchi, J A ^c,d   Alessandrini, M ^b   Richieri, R ^a,b   Faget Agius, C ^a,b   Auquier, A ^b   Lancon C ^a,b   Boyer, L ^b  

^a La Conception University Hospital   (France)

^b AIX MARSEILLE UNIVERSITY   (France)

^c HÔPITAL PELLEGRIN   (France)

^d CNRS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN;

ADULT; CHRONIC DISEASE; COMPLICATION; CROSS-SECTIONAL STUDY; FEMALE; HUMAN; INFLAMMATION; MALE; MIDDLE AGED; QUALITY OF LIFE; RISK FACTOR; SCHIZOPHRENIA; YOUNG ADULT;

ADULT; C-REACTIVE PROTEIN; CHRONIC DISEASE; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; QUALITY OF LIFE; RISK FACTORS; SCHIZOPHRENIA; YOUNG ADULT;

EID: 84930668669     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep10793     Document Type: Article

References (60)

1. McGrath, J., Saha, S., Chant, D. & Welham, J. Schizophrenia: A Concise Overview of Incidence, Prevalence, and Mortality. Epidemiol. Rev. 30, 67-76 (2008).
2. Bruijnzeel, D. & Tandon, R. The Concept of Schizophrenia: From the 1850s to the DSM-5. Psychiatr. Ann. 41, 289-295 (2011).
3. Dickinson, D., Iannone, V. N., Wilk, C. M. & Gold, J. M. General and specific cognitive deficits in schizophrenia. Biol. Psychiatry 55, 826-833 (2004).
4. Awad & Voruganti. Measuring quality of life in patients with schizophrenia: an update. PharmacoEconomics 30, 183-195 (2012).
5. Boyer, L. et al. Measuring quality of life in patients with schizophrenia: an overview. Expert Rev. Pharmacoecon. Outcomes Res. 13, 343-349 (2013).
6. Adelufosi, A. O., Ogunwale, A., Abayomi, O. & Mosanya, J. T. Socio-demographic and clinical correlates of subjective quality of life among Nigerian outpatients with schizophrenia. Psychiatry Res. 209, 320-325 (2013).
7. Hsiao, C.-Y., Hsieh, M.-H., Tseng, C.-J., Chien, S.-H. & Chang, C.-C. Quality of life of individuals with schizophrenia living in the community: relationship to socio-demographic, clinical and psychosocial characteristics: Quality of life of individuals with schizophrenia. J. Clin. Nurs. 21, 2367-2376 (2012).
8. Boyer, L., Baumstarck, K., Guedj, E. & Auquier, P. What's wrong with quality-of-life measures? A philosophical reflection and insights from neuroimaging. Expert Rev. Pharmacoecon. Outcomes Res. 14, 767-769 (2014).
9. Hamer, M. & Chida, Y. Life satisfaction and inflammatory biomarkers: The 2008 Scottish Health Survey1: Life satisfaction and C-reactive protein. Jpn. Psychol. Res. 53, 133-139 (2011).
10. Nowakowski, A. C. Chronic inflammation and quality of life in older adults: a cross-sectional study using biomarkers to predict emotional and relational outcomes. Health Qual. Life Outcomes 12, 141 (2014).
11. Cummings, D. M., King, D. E. & Mainous, A. G. C-Reactive Protein, Antiinflammatory Drugs, and Quality of Life in Diabetes. Ann. Pharmacother. 37, 1593 (2003).
12. Miller, B. J., Gassama, B., Sebastian, D., Buckley, P. & Mellor, A. Meta-Analysis of Lymphocytes in Schizophrenia: Clinical Status and Antipsychotic Effects. Biol. Psychiatry 73, 993-999 (2013).
13. Miller, B. J., Buckley, P., Seabolt, W., Mellor, A. & Kirkpatrick, B. Meta-Analysis of Cytokine Alterations in Schizophrenia: Clinical Status and Antipsychotic Effects. Biol. Psychiatry 70, 663-671 (2011).
14. Flatow, J., Buckley, P. & Miller, B. J. Meta-Analysis of Oxidative Stress in Schizophrenia. Biol. Psychiatry 74, 400-409 (2013).
15. Miller, B. J., Culpepper, N. & Rapaport, M. H. C-reactive protein levels in schizophrenia: a review and meta-Analysis. Clin. Schizophr. Relat. Psychoses 7, 223-230 (2014).
16. Akanji, A. O., Ohaeri, J. U., Al-Shammri, S. & Fatania, H. R. Association of blood levels of C-reactive protein with clinical phenotypes in Arab schizophrenic patients. Psychiatry Res. 169, 56-61 (2009).
17. Fan, X. et al. Elevated serum levels of C-reactive protein are associated with more severe psychopathology in a subgroup of patients with schizophrenia. Psychiatry Res. 149, 267-271 (2007).
18. Fawzi, M. H., Fawzi, M. M., Fawzi, M. M. & Said, N. S. C-reactive protein serum level in drug-free male Egyptian patients with schizophrenia. Psychiatry Res. 190, 91-97 (2011).
19. Dickerson, F., Stallings, C., Origoni, A., Boronow, J. & Yolken, R. C-reactive protein is associated with the severity of cognitive impairment but not of psychiatric symptoms in individuals with schizophrenia. Schizophr. Res. 93, 261-265 (2007).
20. Lasi, D. et al. Metabolic syndrome and inflammation markers in patients with schizophrenia and recurrent depressive disorder. Psychiatr. Danub. 26, 214-219 (2014).
21. Sicras-Mainar, A., Rejas-Gutiérrez, J., Navarro-Artieda, R. & Blanca-Tamayo, M. C-reactive protein as a marker of cardiovascular disease in patients with a schizophrenia spectrum disorder treated in routine medical practice. Eur. Psychiatry 28, 161-167 (2013).
22. American Psychiatric Association. Diagnostic and statistical manual-text revision (DSM-IV-TRim, 2000). (American Psychiatric Association, 2000).
23. WMA. [The Helsinki Declaration of the World Medical Association (WMA). Ethical principles of medical research involving human subjects]. Pol. Merkur. Lek. Organ Pol. Tow. Lek. 36, 298-301 (2014).
24. Heatherton, T. F., Kozlowski, L. T., Frecker, R. C. & Fagerström, K. O. The Fagerström Test for Nicotine Dependence: a revision of the Fagerström Tolerance Questionnaire. Br. J. Addict. 86, 1119-1127 (1991).
25. Saunders, J. B., Aasland, O. G., Babor, T. F., de la Fuente, J. R. & Grant, M. Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO Collaborative Project on Early Detection of Persons with Harmful Alcohol Consumption--II. Addict. Abingdon Engl. 88, 791-804 (1993).
26. Kay, S. R., Opler, L. A. & Fiszbein, A. Significance of positive and negative syndromes in chronic schizophrenia. Br. J. Psychiatry J. Ment. Sci. 149, 439-448 (1986).
27. Lançon, C., Reine, G., Llorca, P. M. & Auquier, P. Validity and reliability of the French-language version of the Positive and Negative Syndrome Scale (PANSS). Acta Psychiatr. Scand. 100, 237-243 (1999).
28. Lieberman, J. A. et al. Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia. N. Engl. J. Med. 353, 1209-1223 (2005).
29. Meyer, J. M. et al. Inflammatory Markers in Schizophrenia: Comparing Antipsychotic Effects in Phase 1 of the Clinical Antipsychotic Trials of Intervention Effectiveness Study. Biol. Psychiatry 66, 1013-1022 (2009).
30. Gupta, A., Dadheech, G., Yadav, D., Sharma, P. & Gautam, S. Metabolic Issues in Schizophrenic Patients Receiving Antipsychotic Treatment. Indian J. Clin. Biochem. 29, 196-201 (2014).
31. Auquier, P. et al. Toward Meeting the Needs of Homeless People with Schizophrenia: The Validity of Quality of Life Measurement. PLoS ONE 8, e79677 (2013).
32. Baumstarck, K. et al. Self-reported quality of life measure is reliable and valid in adult patients suffering from schizophrenia with executive impairment. Schizophr. Res. 147, 58-67 (2013).
33. Boyer, L. et al. The development of the S-QoL 18: A shortened quality of life questionnaire for patients with schizophrenia. Schizophr. Res. 121, 241-250 (2010).
34. Caqueo-Urízar, A., Boyer, L., Boucekine, M. & Auquier, P. Spanish cross-cultural adaptation and psychometric properties of the Schizophrenia Quality of Life short-version questionnaire (SQoL18) in 3 middle-income countries: Bolivia, Chile and Peru. Schizophr. Res. 159, 136-143 (2014).
35. Pearson, T. A. Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: A Statement for Healthcare Professionals From the Centers for Disease Control and Prevention and the American Heart Association. Circulation 107, 499-511 (2003).
36. Wysokiski, A., Margulska, A., Strzelecki, D. & Koszewska, I. Levels of C-reactive protein (CRP) in patients with schizophrenia, unipolar depression and bipolar disorder. Nord. J. Psychiatry 1-8 (2014). doi:10.3109/08039488.2014.984755
37. Dickerson, F. et al. C-reactive protein is elevated in schizophrenia. Schizophr. Res. 143, 198-202 (2013).
38. Van Os, J. & Kapur, S. Schizophrenia. The Lancet 374, 635-645 (2009).
39. Morozink, J. A., Friedman, E. M., Coe, C. L. & Ryff, C. D. Socioeconomic and psychosocial predictors of interleukin-6 in the MIDUS national sample. Health Psychol. Off. J. Div. Health Psychol. Am. Psychol. Assoc. 29, 626-635 (2010).
40. Brotman, D. J., Golden, S. H. & Wittstein, I. S. The cardiovascular toll of stress. Lancet 370, 1089-1100 (2007).
41. Hamer, M. & Steptoe, A. Association between physical fitness, parasympathetic control, and proinflammatory responses to mental stress. Psychosom. Med. 69, 660-666 (2007).
42. Berk, M. et al. So depression is an inflammatory disease, but where does the inflammation come from? BMC Med. 11, 200 (2013).
43. Pantell, M. et al. Social isolation: a predictor of mortality comparable to traditional clinical risk factors. Am. J. Public Health 103, 2056-2062 (2013).
44. Yang, Y. C., McClintock, M. K., Kozloski, M. & Li, T. Social Isolation and Adult Mortality: The Role of Chronic Inflammation and Sex Differences. J. Health Soc. Behav. 54, 182-202 (2013).
45. Donoho, C. J., Crimmins, E. M. & Seeman, T. E. Marital Quality, Gender, and Markers of Inflammation in the MIDUS Cohort. J. Marriage Fam. 75, 127-141 (2013).
46. Sbarra, D. A. Marriage Protects Men from Clinically Meaningful Elevations in C-Reactive Protein: Results from the National Social Life, Health, and Aging Project (NSHAP): Psychosom. Med. 71, 828-835 (2009).
47. Boyer, L. et al. Quality of life is predictive of relapse in schizophrenia. BMC Psychiatry 13, (2013).
48. Dantzer, R., O'Connor, J. C., Freund, G. G., Johnson, R. W. & Kelley, K. W. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat. Rev. Neurosci. 9, 46-56 (2008).
49. Dantzer, R. & Kelley, K. W. Twenty years of research on cytokine-induced sickness behavior. Brain. Behav. Immun. 21, 153-160 (2007).
50. Gruenewald, T. L., Cohen, S., Matthews, K. A., Tracy, R. & Seeman, T. E. Association of socioeconomic status with inflammation markers in black and white men and women in the Coronary Artery Risk Development in Young Adults (CARDIA) study. Soc. Sci. Med. 69, 451-459 (2009).
51. Pollitt, R. A. et al. Cumulative life course and adult socioeconomic status and markers of inflammation in adulthood. J. Epidemiol. Community Health 62, 484-491 (2008).
52. Bazzano, L. A., He, J., Muntner, P., Vupputuri, S. & Whelton, P. K. Relationship between cigarette smoking and novel risk factors for cardiovascular disease in the United States. Ann. Intern. Med. 138, 891-897 (2003).
53. Hermsdorff, H. H. M., Zulet, M. A., Puchau, B. & Martínez, J. A. Central Adiposity Rather Than Total Adiposity Measurements Are Specifically Involved in the Inflammatory Status from Healthy Young Adults. Inflammation 34, 161-170 (2011).
54. Yanbaeva, D. G., Dentener, M. A., Creutzberg, E. C., Wesseling, G. & Wouters, E. F. M. Systemic effects of smoking. Chest 131, 1557-1566 (2007).
55. De Heredia, F. P., Gómez-Martínez, S. & Marcos, A. Obesity, inflammation and the immune system. Proc. Nutr. Soc. 71, 332-338 (2012).
56. Singh, B. & Chaudhuri, T. K. Role of C-reactive protein in schizophrenia: An overview. Psychiatry Res. 216, 277-285 (2014).
57. Boyer, L. et al. Neurophysiological correlates of metabolic syndrome and cognitive impairment in schizophrenia: A structural equation modeling approach. Psychoneuroendocrinology 50, 95-105 (2014).
58. Boyer, L. et al. Association of metabolic syndrome and inflammation with neurocognition in patients with schizophrenia. Psychiatry Res. 210, 381-386 (2013).
59. Boyer, L. et al. Insight into illness, neurocognition and quality of life in schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 36, 271-276 (2012).
60. Tolman, A. W. & Kurtz, M. M. Neurocognitive Predictors of Objective and Subjective Quality of Life in Individuals With Schizophrenia: A Meta-Analytic Investigation. Schizophr. Bull. 38, 304-315 (2012).